Parkinson’s News Forums Forums Parkinson’s Research Nuplazid Does Not Lead to Different Mortality Risk Compared to Other Antipsychotics

  • Nuplazid Does Not Lead to Different Mortality Risk Compared to Other Antipsychotics

    Posted by forum-moderator on October 8, 2018 at 7:44 am

    Treatment with Nuplazid (pimavanserin) does not lead to a different mortality risk compared to the antipsychotic medication Seroquel (quetiapine), or to combination treatment with both medications, in patients with Parkinson’s psychosis, according to results from a large study.

    Read a summary of the study and its findings here.

    What are your thoughts on this news?

    replied 5 years, 5 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.